More recently, in invasive breast cancer, patients with a high CD8+/eTreg ratio achieved significantly higher pathological complete response (pCR) rates following neoadjuvant chemotherapy compared with those with low ratios (118). This evidence concerns the gene CD8A and invasive breast carcinoma.